Related Experiment Video

Updated: Jun 13, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Myricetin inhibits IL-1beta-induced inflammatory mediators in SW982 human synovial sarcoma cells

Young Soon Lee1, Eun Mi Choi

  • 1Department of Food & Nutrition, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, South Korea.

International Immunopharmacology
|April 21, 2010
PubMed

Insights

Myricetin, a natural compound, effectively reduces key inflammatory markers like IL-6 and MMP-1 in rheumatoid arthritis (RA) synovial cells. It achieves this by inhibiting crucial signaling pathways, including JNK and p38 MAPK.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) involves inflammatory mediators from synovial fibroblasts that damage cartilage and bone.
  • Understanding cellular mechanisms in RA is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the effects of myricetin on inflammatory cytokine and matrix metalloproteinase (MMP) production.
  • To examine the impact of myricetin on mitogen-activated protein kinases (MAPKs) in IL-1beta-stimulated synovial cells.

Main Methods:

  • Utilized SW982 synovial cells stimulated with IL-1beta.
  • Assessed the production of IL-6 and MMP-1.
  • Measured the phosphorylation levels of JNK and p38 MAPK.

Main Results:

  • Myricetin significantly reduced IL-1beta-induced production of IL-6 and MMP-1.
  • Myricetin diminished the phosphorylation of JNK and p38 MAPK signaling pathways.
  • Demonstrated myricetin's inhibitory effect on inflammatory mediators in synovial cells.

Conclusions:

  • Myricetin shows potential in mitigating RA-associated inflammation.
  • Inhibition of JNK and p38 MAPK pathways is a key mechanism for myricetin's action.
  • Myricetin may serve as a therapeutic agent for rheumatoid arthritis.

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...